SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Samrat Pharmachem informs about approval of un-audited financial results

10 Feb 2022 Evaluate

Samrat Pharmachem has informed that the Board of Directors of the Company at its meeting held today i.e., Thursday, February 10, 2022, has considered and took on record the attached Un-Audited Standalone Financial Results of the Company for the quarter ended December 31, 2021, which is enclosed along with the Limited Review Report of the Statutory Auditor of the Company. The meeting of the Board of Directors of the Company commenced at 14:30 hrs and concluded at 15:30 hrs.

The above information is a part of company’s filings submitted to BSE.

Samrat Pharmachem Share Price

218.90 -4.25 (-1.90%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×